Format

Send to

Choose Destination
Expert Rev Vaccines. 2014 Aug;13(8):1001-12. doi: 10.1586/14760584.2014.932253. Epub 2014 Jun 24.

Candida antigens and immune responses: implications for a vaccine.

Author information

1
Department of Enfermería 1, Universidad del País Vasco UPV/EHU, Bilbao, Spain.

Abstract

Superficial candidiasis of the oral cavity, vagina and the skin are common mild infections though they may be recalcitrant, as in the case of recurrent vaginitis or denture stomatitis. However, in debilitated people with immune deficiencies, Candida can cause serious invasive infections with high mortality. Both types of patients could benefit from the development of vaccines and monoclonal or polyclonal antibodies of utility for a passive immunization, according to their immune status. Several antigens as mannans, β-glucans, various adhesins, heat shock protein 90 and acid secreted proteinases can be very useful for the vaccines development. There is a broad and sound experience with many of these antigens in animal models, mainly in rabbits and mice. However, only two vaccines, based on recombinant antigens (rAls3p-N and rSap2t) are currently being tested in clinical trials.

KEYWORDS:

Candida albicans; Hsp90; betaglucan; candidiasis; mannan; monoclonal antibody; rAls3p-N; rHyr1p; rSap2t; vaccine

PMID:
24957934
DOI:
10.1586/14760584.2014.932253
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center